Neurosense Therapeutics Ltd (NRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,759 | 7,089 | 1,359 | 3,543 | 4,411 |
| Marketable Securities | 37 | 38 | 3,092 | 3,583 | 4,056 |
| Receivables | 309 | 434 | 567 | 255 | 425 |
| TOTAL | $5,105 | $7,561 | $5,018 | $7,381 | $8,892 |
| Non-Current Assets | |||||
| PPE Net | 88 | 93 | 84 | 77 | 55 |
| Investments And Advances | 21 | 23 | 23 | 23 | 34 |
| Other Non-Current Assets | 172 | 191 | 210 | 229 | 249 |
| TOTAL | $281 | $307 | $317 | $329 | $338 |
| Total Assets | $5,386 | $7,868 | $5,335 | $7,710 | $9,230 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,809 | 3,005 | 1,793 | 1,726 | 811 |
| TOTAL | $2,809 | $3,005 | $1,793 | $1,726 | $811 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 2,689 | 6,304 | 527 | 218 | 400 |
| TOTAL | $2,773 | $6,408 | $653 | $365 | $573 |
| Total Liabilities | $5,582 | $9,413 | $2,446 | $2,091 | $1,384 |
| Shareholders' Equity | |||||
| Retained earnings | -29,116 | -29,900 | -24,675 | -20,786 | -17,636 |
| TOTAL | $-196 | $-1,545 | $2,889 | $5,619 | $7,846 |
| Total Liabilities And Equity | $5,386 | $7,868 | $5,335 | $7,710 | $9,230 |